CD8A and type 1 diabetes mellitus: The frequency of S‐specific CD8+ T cells after the SARS‐CoV‐2 vaccine booster dose was similar among ND, T1D, and T2D participants, and no significant differences were observed in the percentage of individuals in whom S‐specific CD8+ T cells were detected between the ND and T1D groups (Figure 5A).